Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys), With Ribavirin (Copegus) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment.

Trial Profile

A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys), With Ribavirin (Copegus) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PROVE-1
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 24 Sep 2009 A pooled analysis of data from the PROVE 1 and PROVE 2 trials will be presented in a poster session at AASLD 2009 on Nov 3rd.
    • 30 Apr 2009 Primary endpoint results published in New England Journal of Medicine 360: 1827-1838, No. 18, 30 Apr 2009.
    • 25 Sep 2008 Results will be presented at AASLD in Oct/Nov 2008.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top